Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Chronic Atopic Dermatitis
NCT01806662Phase 2Completed
- Sponsor
- The Rockefeller University
- Start
- Mar 2013
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ustekinumab in atopic dermatitis (AD) (2 arms), sponsored by The Rockefeller University. Primary endpoint: Proportion of SCORAD-50 Response at 16 weeks. Started Mar 2013; status: completed.
02
Drugs
ustekinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01806662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806662.